Tirzepatide and Zepbound prescribing puts medspas, nurse practitioners, and injectors in a gray zone most compliance templates never anticipated — weekly titration, off-label dosing questions, and a patient population that expects fast turnaround. This guide breaks down what a medical director for tirzepatide clinics actually needs to cover in 2026, and which oversight setups hold up under a board audit.
- A medical director for tirzepatide clinics needs sign-off on titration protocols, not just a signature on a wall certificate — Buy this model, Skip the rubber-stamp version.
- Good faith exams before the first tirzepatide or Zepbound dose are non-negotiable in most states with injectable weight-loss rules in 2026.
- Chart review cadence matters more for GLP-1 patients than for Botox because dosing changes every 4 to 8 weeks.
- Bulk collaborating physician plans make sense once a group runs tirzepatide programs across 3 or more locations.
- Skip any collaborating physician agreement that doesn’t name weight-loss injectables specifically.
Why this matters
Tirzepatide clinics are not Botox clinics with a different drug in the fridge. The FDA approved Zepbound as a branded tirzepatide product in November 2023, and compounded tirzepatide came off the FDA's drug shortage list in 2024 — both events changed what state boards expect from oversight. A generic aesthetics collaborating agreement written for neurotoxins and fillers rarely mentions weight-loss injectables at all, which leaves a gap the first time a state investigator asks who reviewed a patient's dose escalation.
Good faith exams for semaglutide clinics work the same way for tirzepatide programs: an exam before the first prescription, documented and dated, tied to a named physician. Skip that step and the entire program runs on an agreement that doesn't match what the clinic actually sells.
Who this is for
This is written for medspa owners, nurse practitioners, and injectors who added tirzepatide or Zepbound to their service menu and now need a physician relationship that actually covers GLP-1 prescribing — not just Botox and filler. It's also for multi-location groups scaling a weight-loss vertical who need oversight that survives an audit across every state they operate in.
What to look for in a medical director for tirzepatide clinics
GLP-1-specific scope language
A collaborating agreement that only lists "aesthetic injectables" doesn't cover tirzepatide. The scope section needs to name weight-loss medications, dosing ranges, and titration authority explicitly, or the whole document is decorative.
Titration review cadence
Tirzepatide and Zepbound doses typically step up every 4 weeks, from a 2.5mg starting dose toward maintenance levels of 5mg, 10mg, or 15mg. A medical director who reviews charts once a year misses every titration decision that actually carries clinical risk.
Good faith exam workflow
Most states with injectable weight-loss rules expect a documented good faith exam before the first dose. The workflow needs a named exam date, a physician signature, and a system for flagging patients who haven't had one — not a verbal assurance that "someone looked at the chart."
Multi-state coverage if you run telehealth
Tirzepatide clinics increasingly prescribe over telehealth across state lines. A single collaborating physician licensed in one state does not cover a patient sitting in another — this needs a structure built for multi-state rules, not an afterthought.
Response time on chart flags
When a tirzepatide patient reports a side effect or a dosing question outside protocol, the oversight arrangement needs a physician who responds inside days, not weeks. Slow response time on flagged charts is the single biggest gap boards cite in enforcement actions.
Pricing that scales with patient volume
A flat per-location fee makes sense for a single clinic. A group running tirzepatide across five locations needs pricing that reflects patient volume and chart-review load, not a flat rate that punishes growth.
Get tirzepatide oversight built right
Talk to US Medical Directors about GLP-1-specific collaborating agreements.
Top picks for tirzepatide and Zepbound clinics
The baseline setup — collaborating physician agreement built for weight loss
Every tirzepatide clinic needs a base agreement, and the version that works names the drug class specifically instead of relying on generic aesthetics language. A collaborating physician for weight loss clinics structure covers dosing authority, titration sign-off, and scope in one document. Buy this as the foundation before adding anything else.
The compliance layer — good faith exams before first dose
This is the piece most clinics skip until a board complaint forces the issue. Every new tirzepatide patient needs a documented exam tied to a physician before the first injection or prescription goes out, and the exam date has to live in the chart, not in someone's memory. Buy this as a standing requirement, not a one-time setup task.
The audit trail — chart review for titration monitoring
Tirzepatide dosing changes every 4 to 8 weeks, and a chart review service for weight-loss clinics catches the patients whose escalation doesn't match protocol before it becomes an incident report. Clinics running 20 or more active GLP-1 patients need this reviewed on a defined cycle, not annually. Buy if patient volume exceeds a handful; Consider for very small solo practices still ramping up.
The scale play — bulk plans for multi-location groups
Once a group runs tirzepatide programs across three or more locations, per-clinic contracts start costing more than a bulk collaborating physician plan and create inconsistent oversight standards between sites. This model standardizes the scope language and the exam workflow across every location under one agreement. Buy for groups past three sites; Skip if you're still a single clinic — the bulk pricing math doesn't work yet.
The adjacent model — wellness and longevity clinic oversight
Some tirzepatide programs sit inside a broader wellness or longevity clinic offering hormone therapy and IV services alongside GLP-1s. That combination needs a medical director comfortable signing off on multiple drug classes at once, not one specialized only in aesthetics. Consider this model if tirzepatide is one of several verticals under one roof; Skip it if tirzepatide is the entire business — a weight-loss-specific agreement fits better.
What to avoid
- A medical director in name only. A physician who signs the agreement once and never reviews a chart again is a liability, not oversight — boards look for actual activity, not a signature.
- A template agreement copied from a Botox clinic. If the document never mentions tirzepatide, Zepbound, or GLP-1 dosing, it doesn't cover what the clinic is actually doing.
- No documented good faith exam trail. Verbal sign-off doesn't hold up. Every patient needs a dated, physician-attributed exam record before the first dose.
Verdict comparison
| Setup | Best for | Titration coverage | Verdict |
|---|---|---|---|
| Baseline collaborating agreement | Single-location tirzepatide clinics | Named in scope | Buy |
| Good faith exam workflow | Every clinic, any size | Required before first dose | Buy |
| Chart review add-on | Clinics with 20+ active patients | Reviewed on a defined cycle | Buy |
| Bulk collaborating plan | Groups with 3+ locations | Standardized across sites | Buy for groups / Skip for solo |
| Wellness clinic oversight | Multi-vertical practices | Covers GLP-1 plus other drug classes | Consider |
FAQ
What does a medical director do for a tirzepatide clinic?
A medical director for a tirzepatide clinic reviews prescribing protocols, signs off on titration decisions, and oversees good faith exams before the first dose. In 2026, that role also covers documentation that holds up if a state board audits the practice.
Is a medical director required for Zepbound prescribing?
Requirements depend on the state and who’s writing the prescription, but nurse practitioners and non-physician providers generally need a collaborating physician relationship to prescribe Zepbound legally. Check your state’s specific supervision rules before launching a program.
How much does a collaborating physician cost for a weight-loss clinic in 2026?
Pricing varies by state, patient volume, and whether the clinic needs chart review bundled in. Groups running multiple locations typically save by moving to a bulk plan instead of paying per-clinic rates.
Can a nurse practitioner prescribe tirzepatide without physician oversight?
In most states, no — NPs need a collaborating physician agreement that specifically covers weight-loss prescribing. Full practice authority states have different rules, so this depends heavily on location.
What’s the difference between a good faith exam and chart review for GLP-1 patients?
A good faith exam happens once, before the first dose, to confirm the patient is a safe candidate. Chart review happens on an ongoing basis to monitor titration and catch dosing issues as treatment continues.
Do telehealth tirzepatide clinics need a collaborating physician in every state?
Yes, in most cases — a physician licensed in one state generally can’t supervise prescribing for a patient physically located in another state without meeting that state’s telehealth rules.
How often should charts be reviewed for tirzepatide patients?
Tirzepatide doses typically escalate every 4 to 8 weeks, so chart review on a similar cadence catches problems before the next dose increase. Annual review is too infrequent for a titrating medication.
Is compounded tirzepatide still legal to prescribe in 2026?
Compounded tirzepatide came off the FDA’s drug shortage list in 2024, which changed the legal basis for compounding it under shortage exceptions. Clinics still offering compounded versions in 2026 need to verify their compounding pharmacy’s current legal standing.
One last thing
Compounded tirzepatide came off the FDA's shortage list in 2024 — that single change quietly invalidated the legal basis a lot of clinics were relying on to offer compounded versions. Any tirzepatide program still running on a 2023-era compliance setup needs a fresh look in 2026, not just a renewal signature.
Related guides
- Bulk collaborating physician plans for medspa groups
- How to hire a medical director for your aesthetics practice
